Biomatrix's synovial fluid mimic approved
This article was originally published in Clinica
Executive Summary
The FDA has approved Biomatrix' elastoviscous fluid Synvisc for treatment of osteoarthritis of the knee. As a result Biomatrix will receive a $12 million milestone payment from Wyeth-Ayerst Laboratories, which will market and distribute the product in the US.